BHC logo

BAUSCH HEALTH COS INC

BHCNYSE
πŸ† #1714 by market capEarnings Oct 28 Β· PostUS Equity
$6.92β–² $0.61 (+9.67%)
πŸŒ™ After hours$7.85β–² 13.44%Regular close Β· extended-hours price shown
πŸ””
Track BHC
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 9.7%
7dβ–² 6.8%
14dβ–² 9.5%
30dβ–² 19.3%
ytdβ–Ό 0.3%
1yβ–² 17.6%
🏦Market Cap
$2.59B
Small Cap
πŸ“ˆRevenue Growth (YoY)
6.7%
Slowing
πŸ“ŠGross Margin
79.0%
High
πŸ’΅FCF Margin
12.6%
Healthy
βš–οΈP/S Ratio
0.2x
Cheap
Otter Score
88
Excellent

Trading Snapshot

Day Range
$6.25 – $6.95
52-Week Range
$4.33 – $8.00
Volume (shares)
7,995,569
Avg Volume (shares)
β€”
Shares Outstanding
374.0M
Next Earnings
2026-10-28

Fundamentals Snapshot

Annual Revenue
$10.27B
Last Q Revenue
$2.85B
P/E Ratio
-2.0
P/S Ratio
0.2x
EPS (TTM)
$-2.26
Dividend Yield
0.00%
Dilution (1yr)
βˆ’0.4%
BHC logo

BAUSCH HEALTH COS INC

BHC
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$10.3Bβ–² +6.7% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
70.7%β–Ό βˆ’0.6% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$2.2Bβ–² +41.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$1.0Bβ–Ό βˆ’20.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
370.5Mβ–Ό βˆ’0.4% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$19.9Bβ–² +$550M YoY
StockOtter Β· stockotter.space

About BAUSCH HEALTH COS INC

Bausch Health Companies Inc., together with its associated entities, is engaged in the development, manufacturing, and commercialization of a diverse portfolio of pharmaceutical products, medical devices, and over-the-counter remedies. Its primary therapeutic focus areas include ophthalmology, digestive health, and dermatology. The enterprise conducts its operations through five principal divisions: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment is dedicated to vision care, encompassing surgical instruments, consumer eye health products, and ophthalmic pharmaceuticals. Salix specializes in delivering gastroenterology-specific products exclusively within the United States. The International Rx division markets Solta products, a range of branded and generic pharmaceuticals, OTC items, medical devices, and Bausch + Lomb offerings across diverse geographies including Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. Ortho Dermatologics focuses on dermatological products in the U.S., in addition to distributing Solta's medical aesthetic devices globally. Finally, the Diversified Products segment supplies pharmaceutical solutions for neurology and other therapeutic categories, as well as generic medications and dental products, all within the U.S. The company was formerly known as Valeant Pharmaceuticals International, Inc., officially changing its name to Bausch Health Companies Inc. in July 2018. Its corporate headquarters are located in Laval, Canada.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Excellent
88/100

Analyst Ratings

β“˜
Consensus
Sell
8 analysts
Strong Buy0
Buy0
Hold4
Sell3
Strong Sell1
Ratings as of Oct 2026

Latest News & Updates

Zacks Investment ResearchΒ·6h ago

Bausch (BHC) Reports Q3 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Bausch (BHC) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the

Zacks Investment ResearchΒ·6h ago

Bausch Health (BHC) Surpasses Q3 Earnings and Revenue Estimates

Bausch Health (BHC) came out with quarterly earnings of $1.77 per share, beating the Zacks Consensus Estimate of $1.08 per share. This compares to earnings of $1.16 per share a year ago.

MarketBeatΒ·7h ago

What Bausch Health Cos (BHC) Said on Its Q3 Earnings Call

Bausch Health Cos NYSE: BHC raised its full-year 2026 outlook for the second consecutive quarter after reporting third-quarter growth across its operating segments, led by Salix and supported by international operations

PRNewsWireΒ·11h ago

Bausch Health Announces Full Redemption of 8.500% Senior Notes Due 2027

LAVAL, QC, Oct. 28, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that its subsidiary, Bausch Health Americas, Inc., will issue an irrevocable notice of redemption dated as of Octo

PRNewsWireΒ·11h ago

Bausch Health Announces US$50 Million Share Repurchase Program

LAVAL, QC, Oct. 28, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that its Board of Directors has authorized a share repurchase program under which the Company may repurchase its c

PRNewsWireΒ·11h ago

BAUSCH HEALTH ANNOUNCES THIRD QUARTER 2026 RESULTS, RAISES GUIDANCE

Third Quarter Consolidated Revenues of $2.94 billion, up 10% on a Reported basis and 8% on an Organic1Β basis over the prior year period GAAP Net Income Attributable to Bausch Health of $436 million and GAAP Net Income of